Medical Condition News

RSS

Biological activity of Curis' CUDC-101 HDAC, EGFR and HER2 inhibitor published in Cancer Research

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that a research paper describing the biological activity of its HDAC, EGFR and HER2 inhibitor, CUDC-101, was published online in the journal Cancer Research and also will be published in an upcoming print version of the journal.

23 Apr 2010

Data from pivotal study of Marqibo in ALL patients to be presented at ASCO meeting

Hana Biosciences, a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that complete data from its pivotal study of Marqibo in patients with relapsed/refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia, have been accepted for an oral podium presentation at the 46th Annual Meeting of the American Society of Clinical Oncology to be held June 4-8, 2010 in Chicago, Illinois.

23 Apr 2010

FDA Advisory Committees vote against approval of Acurox NDA

Acura Pharmaceuticals, Inc. and King Pharmaceuticals®, Inc. today announced that the U.S. Food and Drug Administration's (FDA) Anesthetic and Life Support Drugs and Drug Safety and Risk Management Committees voted that they do not have enough evidence to support the approval of the New Drug Application (NDA) for Acurox® (oxycodone HCl and niacin) Tablets for the treatment of moderate to severe pain, considering the deterrent effects of niacin as well as the potential deterrent effects of the other features specific to Acurox®.

23 Apr 2010

Physical exercise and computer use may help protect against mild cognitive impairment: Mayo Clinic

A new Mayo Clinic study found that physical exercise and computer use may help protect against mild cognitive impairment, a disorder of the brain that affects nerve cells involved in thinking abilities.

23 Apr 2010

Celator Pharmaceuticals presents data on CPX-351 Liposome Injection and HDPN formulation

Celator Pharmaceuticals today announced data from animal studies demonstrating the superior bone marrow uptake of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, its lead clinical-stage program, as well as the enhanced circulation kinetics and efficacy of its preclinical hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation were presented at the 101st Annual Meeting of the American Association for Cancer Research in Washington, DC (Abstracts 3698 and 5534).

23 Apr 2010

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Pfizer Inc. announced today the discontinuation of the SUN 1170 Phase 3 open-label study of Sutent(r) (sunitinib malate) in advanced hepatocellular carcinoma, or liver cancer. Following a review by the independent Data Monitoring Committee, the study was discontinued based on a higher incidence of serious adverse events in the sunitinib arm compared to the sorafenib arm and the fact that sunitinib did not meet the criteria to demonstrate that it was either superior or non-inferior to sorafenib in the survival of patients with advanced hepatocellular cancer.

23 Apr 2010

Molecular mechanisms of hypertension, its diagnosis and treatment to be focused at ASBMB's symposium

About 1 billion people around the world suffer from hypertension. The molecular mechanisms of this disease, its diagnosis and treatment will be the focus of a lecture series at the American Society for Biochemistry and Molecular Biology's annual meeting in Anaheim, Calif. The talks will take place from Monday, May 26 through Wednesday, April 28 in room 304C of the Anaheim Convention Center.

23 Apr 2010

CRT teams up with The University of Auckland to discover novel treatments for cancer

Cancer Research Technology - Cancer Research UK's development and commercialisation arm has teamed up with The University of Auckland to advance the discovery of new molecular targeted compounds for the treatment of leukaemia.

23 Apr 2010

Amylin, Eli Lilly and Alkermes reply to FDA complete response letter for BYDUREON NDA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the companies have submitted their reply to a complete response letter issued last month by the U.S. Food and Drug Administration (FDA) after review of the New Drug Application (NDA) submission for BYDUREON™ (exenatide for extended-release injectable suspension).

23 Apr 2010

First Edition: April 22, 2010

Kaiser Health News staff writer Phil Galewitz, working in collaboration with USA Today, writes about the Money Follows The Person program: "Richard Hasselbach and Deborah Kadlec met in a nursing home and dreamed of a life together outside its walls. Their health conditions made living on their own a challenge: Hasselbach, 63, is disabled from a stroke and lost a leg to a blocked artery. Kadlec, 52, has multiple sclerosis. They both use wheelchairs and need help with chores such as bathing, cooking and remembering to take their medicines.

22 Apr 2010

Cognitive behavior therapy works better as couples therapy for alcohol-dependent women

Barbara McCrady and Elizabeth Epstein wanted to know whether cognitive behavior therapy worked better for alcohol-dependent women when delivered as couples therapy than when delivered as individual therapy. They reported recently that both treatment methods worked well, but women treated in couples therapy maintained their gains a bit better than those in individual therapy. Also, women suffering from depression in addition to alcohol-dependence did better in couples therapy. Their paper appeared recently in the Journal of Consulting and Clinical Psychology.

22 Apr 2010

Valor Medical's European cerebral aneurysm clinical trial finalized with 30 patients treated

Valor Medical's CEO, H. Clark Adams, announced today that Valor's European clinical trial was finalized with 30 patients treated. Mr. Adams stated, "The trial took longer than expected because there are current approved therapies which were used as a first line of therapy. Patients who were enrolled to be treated with Valor's Neucrylate were not always acceptable candidates for these standard-of-care therapies.

22 Apr 2010

Accredo Health Group selected as sole specialty pharmacy provider of Epoprostenol for Injection

Actelion Pharmaceuticals US, Inc., today announced that it has selected Accredo Health Group, Inc., a wholly-owned subsidiary of Medco Health Solutions, Inc., to serve as the sole specialty pharmacy provider of Epoprostenol for Injection, the only epoprostenol formulated to provide up to 24-hour stability at room temperature without the use of ice packs.

22 Apr 2010

Actelion Pharmaceuticals launches Epoprostenol for Injection for treatment of primary pulmonary hypertension

Actelion Pharmaceuticals US, Inc. today announced the commercial availability of Epoprostenol for Injection, an improved formulation of epoprostenol that is stable at room temperature, for the treatment of primary pulmonary hypertension and pulmonary hypertension associated with scleroderma spectrum of disease in NYHA Class III and Class IV patients.

22 Apr 2010

New campaign highlights dangers of carrying excess weight around waist

Cancer Research UK has joined forces with the British Heart Foundation and Diabetes UK to launch a new campaign to raise awareness of the dangers of carrying excess weight around the waist.

22 Apr 2010

Cancers deficient in ASS enzyme allow ADI-PEG 20 to inhibit cancer cell growth

Polaris Group scientists and university collaborators reported at the American Association for Cancer Research (AACR), that a number of different cancers have a deficiency in a specific enzyme, argininosuccinate synthetase (ASS), which allows pegylated arginine deiminase (ADI-PEG 20) to inhibit cancer cell growth.

22 Apr 2010

IL-10 Gene Therapy helps repair damaged lungs found unfit for transplant

Promising research brings hope for the almost two thousand lung transplant candidates who currently make up The United Network for Organ Sharing's (UNOS) wait list. A new technique that uses gene therapy to help repair damaged lungs previously found unfit for transplant shows promise for addressing the critical shortage of healthy donor organs.

22 Apr 2010

Mild Cognitive Impairment Symposium is now 'Symposium on Early Alzheimer's Disease'

This year, the Miami Beach symposium kicked off on a rainy Friday with a new name and a new focus on biomarkers. For seven years, the meeting has been called the Mild Cognitive Impairment Symposium, but that changed this year to the Symposium on Early Alzheimer's Disease. The change comes as a nod to a recent and dramatic shift in how Alzheimer disease is perceived, and what researchers increasingly see as the most promising angle of attack for future therapeutics.

22 Apr 2010

Increase in mammographic density associated with increase of breast cancer in EPT study participants

An increase in breast density appears to be the culprit behind an increase of breast cancer found in women participating in the estrogen and progestin therapy study, a part of the Women's Health Initiative (WHI). That is the finding of a new WHI analysis led by Celia Byrne, PhD, assistant professor at Georgetown Lombardi Comprehensive Cancer Center, and presented during the AACR 101st Annual Meeting 2010 in Washington, DC.

22 Apr 2010

Researchers receive grant to help people living with mental illness tackle tobacco dependence

Researchers at The University of Nottingham have won government funding to improve the services which help people living with serious mental illness to tackle their tobacco dependence.

22 Apr 2010

Medical Condition News

Biological activity of Curis' CUDC-101 HDAC, EGFR and HER2 inhibitor published in Cancer Research

Data from pivotal study of Marqibo in ALL patients to be presented at ASCO meeting

FDA Advisory Committees vote against approval of Acurox NDA

Physical exercise and computer use may help protect against mild cognitive impairment: Mayo Clinic

Celator Pharmaceuticals presents data on CPX-351 Liposome Injection and HDPN formulation

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Molecular mechanisms of hypertension, its diagnosis and treatment to be focused at ASBMB's symposium

CRT teams up with The University of Auckland to discover novel treatments for cancer

Amylin, Eli Lilly and Alkermes reply to FDA complete response letter for BYDUREON NDA

First Edition: April 22, 2010

Cognitive behavior therapy works better as couples therapy for alcohol-dependent women

Valor Medical's European cerebral aneurysm clinical trial finalized with 30 patients treated

Accredo Health Group selected as sole specialty pharmacy provider of Epoprostenol for Injection

Actelion Pharmaceuticals launches Epoprostenol for Injection for treatment of primary pulmonary hypertension

New campaign highlights dangers of carrying excess weight around waist

Cancers deficient in ASS enzyme allow ADI-PEG 20 to inhibit cancer cell growth

IL-10 Gene Therapy helps repair damaged lungs found unfit for transplant

Mild Cognitive Impairment Symposium is now 'Symposium on Early Alzheimer's Disease'

Increase in mammographic density associated with increase of breast cancer in EPT study participants

Researchers receive grant to help people living with mental illness tackle tobacco dependence

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News